Houston-based medical technology company wins overall global health tech competition at Scientific Sessions 2025

Two health care technology companies were named to the American Heart Association Innovators’ Network for their innovative solutions designed to improve cardiovascular disease and stroke patient outcomes

2025-11-10

(Press-News.org) DALLAS, Nov. 10, 2025 — Despite major advances in care, nearly half of U.S. adults live with some form of cardiovascular disease or stroke, according to the American Heart Association®, a relentless force changing the future of health for everyone everywhere. To close this gap, innovative health solutions must reach people where they live, work and play. At its Scientific Sessions 2025, the Association recognized two pioneering companies whose health technologies could help do just that.

Houston-based PolyVascular was named the overall winner of the American Heart Association’s annual Health Tech Competition, earning top honors in the business category. Brainomix of Oxford, England was awarded best in the science category. Both companies will be invited to join the Association’s Center for Health Technology & Innovation Innovators’ Network, a consortium that connects entrepreneurs, providers, researchers and payers to share and advance innovation in cardiovascular and brain health.

The Health Tech Competition is a live forum for health care innovators to present digital solutions for treating or preventing cardiovascular diseases and stroke. Finalists addressed clinical problems such as heart failure, hypertension, congenital heart defects and other pressing issues in cardiovascular, brain and metabolic health.

“The Health Tech Competition is like our own version of Shark Tank, showcasing groundbreaking innovations that have the potential to transform care. What excites me most is seeing science come to life in ways that reach people where they live, work and play,” said Star Jones, attorney, TV personality and American Heart Association national volunteer, who served as one of this year’s judges. “These technologies aren’t just promising—they’re poised to make a real impact.”

Solutions were evaluated based on three key criteria:

Validity: How well is the working prototype or product functioning in the market with customers? Scientific Rigor: How well does validation research use evidence-based health research? Impact: To what extent does the product improve patient outcomes through innovative technology? This year’s finalists included:

PolyVascular (Houston): Developing minimally invasive solutions for children with congenital heart disease, aiming to reduce the need for repeated open-heart surgeries. Brainomix (Oxford, England): Creating AI-powered software to improve stroke diagnosis and treatment decisions. Lumia (Boston): Delivering wearable solutions for people with orthostatic intolerance and chronic blood flow disorders. Noah Labs (Berlin): Transforming voice into a digital biomarker to enable earlier intervention for cardiometabolic diseases. Cambrian Health (San Francisco): Building an AI-powered platform that ensures clinical best practices are seamlessly executed at the point of care. The winning company, PolyVascular, is advancing minimally invasive technology to help children with congenital heart disease avoid repeated open-heart surgeries so they can enjoy healthier, more carefree lives.

“This is a tremendous honor for PolyVascular - we’re especially proud to bring hope to families and children living with congenital heart defects. Our technology—a minimally invasive valve that can be expanded over time to grow with the child—has the potential to dramatically reduce the need for repeated open-heart surgeries,” said Henri Justino, M.D., co-founder of PolyVascular. “The American Heart Association plays a pivotal role in advancing innovative care pathways, and we’re excited that our solution aligns with its guidelines and mission. It’s time these life-changing technologies reach the youngest patients, just as they already do for adults.”

A panel of expert volunteer judges also selected Brainomix as the best science pitch, opening opportunities for the company to connect with scientific and business leaders after Scientific Sessions. Brainomix develops cutting-edge AI software that supports precision medicine, helping doctors make faster, more accurate treatment decisions for stroke and lung fibrosis.

Judges include:

Eric D. Peterson, M.D., M.P.H., FAHA, professor of medicine in the division of cardiology at UT Southwestern Medical Center Lee Shapiro, J.D., volunteer chairman of the board of the American Heart Association and co-founder and managing partner of 7WireVentures Lisa Suennen, managing partner at American Heart Association Ventures Ken Nelson, partner at the Med Tech Innovators Advantage Fund Craig Beam, president of Beam & Associates Tim Benner, chief strategy officer and chief marketing officer of Masimo Henry Peck, chief business officer of LSI Star Jones, lawyer/TV personality, Divorce Court, and American Heart Association national volunteer Lee H. Schwamm, M.D., FAHA, associate dean of digital strategy and transformation at Yale School of Medicine Joseph C. Wu, M.D., Ph.D., FAHA, volunteer past president (2023-24) of the American Heart Association, professor and director at the Stanford Cardiovascular Institute and co-founder of Greenstone Biosciences Michael V. McConnell, M.D., MSEE, clinical professor of medicine at Stanford University School of Medicine Asif Ali, M.D., clinical associate professor of cardiovascular medicine at the University of Texas Medical School in Houston and director at Cena Research Institute Jessica Golbus, M.D., M.S., FAHA, assistant professor at the University of Michigan Ashoo Tandon, M.D., M.S., FAHA, FAAP, FACC, pediatric cardiologist, director of cardiovascular innovation and associate staff at Cleveland Clinic Children’s Dave Albert, M.D., founder of AliveCor Daniel Cantillon, M.D., chief medical officer of Masimo Finalist presentations took place November 8–9 at the Ernest N. Morial Convention Center in New Orleans during Scientific Sessions 2025 — the American Heart Association’s premier global event for advancements in cardiovascular science and medicine.

To learn more about the Health Tech competition, visit: ahahealthtech.org/aha-health-tech-competition-2025.

Additional Resources:

American Heart Association Release: Finalists named in global health technology competition to advance heart and brain health American Heart Association Release: NY AI medical company wins global health tech competition at Scientific Sessions 2024 American Heart Association Release: 5 health technology start-ups finalists in global heart disease solution competition Follow AHA/ASA news on X @HeartNews ###

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public’s health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.

END

ELSE PRESS RELEASES FROM THIS DATE:

Cup of coffee a day may not be harmful for some adults with AFib and could lower episodes

2025-11-10

Research Highlights: During the 6 months after treatment to restore a normal heart rhythm, adults with atrial fibrillation (AFib) who were randomly assigned to drink coffee every day were 39% less likely to have a recurrence of AFib compared to participants assigned to not have any coffee or other caffeinated drinks. The results of the 200-person trial may challenge the common belief that caffeine may spur more abnormal heart rhythms such as AFib. Researchers say it is reasonable for health care professionals to let their AFib patients try naturally caffeinated drinks ...

Heart attack risk halved in adults with heart disease taking tailored vitamin D doses

2025-11-10

Research Highlights: Adults with heart disease prescribed vitamin D in doses tailored to reach blood levels considered optimal for heart health (>40-80 ng/mL) had a reduced risk of heart attack by more than half (52%) compared to those who did not receive monitoring of vitamin D levels. 85% of all study participants had vitamin D levels below 40 ng/mL at enrollment, and nearly 52% of people in the treatment group needed to take more than 5,000 IU of vitamin D each day (more than six times the 800 IU daily value established by the FDA) to reach target blood ...

Phages with fully-synthetic DNA can be edited gene by gene

2025-11-10

A team led by University of Pittsburgh’s Graham Hatfull has developed a method to construct bacteriophages with entirely synthetic genetic material, allowing researchers to add and subtract genes at will. The findings open the field to new pathways for understanding how these bacteria-killing viruses work, and for potential therapy of bacterial infections. As phages’ secrets are revealed, researchers will be able to engineer them with genomes tailor-made to attack specific bacteria, leading to new ways to combat the worsening problem of antibacterial resistance. Contact ...

Investigational daily pill lowered bad cholesterol as much as injectables

2025-11-10

Research Highlights: For people who have experienced a heart attack or stroke, or who are at high risk of one and need further cholesterol lowering, a new daily pill may be a more convenient yet similarly effective option to injectable therapies. The oral medication, enlicitide, lowered LDL cholesterol by up to 60% and could eventually offer an option for people whose LDL levels remain above goal despite lifestyle changes and standard cholesterol medications like statins. A longer, ongoing cardiovascular outcomes study will examine whether enlicitide can reduce the risk of heart attack or stroke. Note: The study featured ...

Researcher seeks to understand delays in language development

2025-11-10

Nancy Brady has been gratified to see the tool she and colleagues pioneered over a decade ago to measure the growth of infants’ pre-speech communication skills translated into several languages and referenced in more than 100 research papers, including a åçnew one published in the Journal of Speech, Language and Hearing Research. Brady, a professor in the University of Kansas Department of Speech-Lanuage-Hearing: Sciences & Disorders, and her now-former graduate student Olivia Boorom were among the co-authors of a new paper ...

Medication still better than procedure for some irregular heartbeat conditions

2025-11-10

Research Highlights: Standard care, which included medication for those eligible, was better than a promising minimally invasive procedure for people with irregular heart rhythms who had high stroke and bleeding risk. The procedure seals off a small pouch of heart tissue, where most blood clots form in people with irregular heartbeat. However, in older people, standard care, including the use of blood thinners when indicated, did a better job at prevention of stroke, blood clots, cardiovascular or unexplained death ...

Understanding how bacteria use “sunscreen” to adapt to climate

2025-11-10

Cyanobacteria, commonly known as blue-green algae, are found almost everywhere in the world—from hot springs to arctic ice to antioxidant smoothies. Part of their extreme adaptability lies within a unique light-harvesting structure called the phycobilisome. These modular antennae both collect energy from sunlight, and adapt to changing light levels in order to provide a sort of sunscreen for the bacteria. One important way that phycobilisomes adapt involves an accessory protein to both sense and protect against too much light. ...

Inaugural Margot and Tom Pritzker Prize for AI in Science Research Excellence announces winners at conference

2025-11-10

The University of Chicago and Caltech announce the recipients of the inaugural Margot and Tom Pritzker Prize for AI in Science Research Excellence, presented during the AI+Science Conference hosted at Caltech on November 10 and 11. This new award recognizes outstanding contributions that jointly advance artificial intelligence and the natural sciences or engineering. “We see AI as a catalyst for human ingenuity—accelerating the scale and pace of discovery in ways that can meaningfully benefit humanity. We hope that this initiative will help scientists to reach farther to explore frontiers once thought unreachable,” said Margot Pritzker and Tom ...

COP webpages emit seven times more carbon than average sites

2025-11-10

Websites produced for COP conferences emit up to seven times more carbon than average internet pages, new research suggests. Ahead of this year’s United Nations climate summit, COP30, researchers have revealed a sharp increase in the carbon emissions generated by the conference’s websites over time. Analysis indicates that between 1995 – when the first Conference of the Parties (COP) was held – and 2024, average emissions from COP conference websites have risen by more than 13,000%. While ...

Successful visualization of the odor discrimination process in an AI-assisted olfactory sensor

2025-11-10

NIMS has been developing chemical sensors as a key component of the artificial olfaction technology (olfactory sensors), with the aim of putting this technology into practical use. In this study, explainable AI (XAI) was used to reveal how chemical sensors discriminate among various odorant molecules. The findings may help guide the selection of receptor materials for developing high-performance chemical sensors capable of detecting odorant molecules. The achievement is expected not only to improve the performance of artificial olfaction but also to advance understanding of human olfactory mechanisms. This ...

LAST 30 PRESS RELEASES:

NAD⁺ restores memory in Alzheimer’s’ disease models by correcting RNA errors

Talking with our hands: Duke study reveals how culture shapes our gestures

Diet alone doesn’t explain divergent health of California Sea Lions in US and Mexico

Blood-platelet screening in midlife could identify early risk for Alzheimer’s disease

One month of clot prevention after a stent was as effective as year-long course for AFib

Ablation reduces stroke risk for AFib and may remove need for some types of blood thinners

Earlier blood transfusion may reduce heart failure, arrhythmia in adults with heart disease

Texas Tech professors awarded $12 million for data center and AI research

Diabetes drug reduced irregular heartbeat events in overweight/obese adults with AFib